康泰生物：上半年营收同比增长15.81% 布局肺炎克雷伯菌疫苗等全球创新品种

Group 1 - The core viewpoint of the article highlights that Kangtai Biological (300601) reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [1] - The company's net profit attributable to shareholders decreased to 37.53 million yuan, reflecting a significant decline of 77.3% compared to the previous year [1] - Basic earnings per share for the company stood at 0.03 yuan [1] Group 2 - The company has been actively engaged in the research and development of globally innovative products, including a vaccine for Klebsiella pneumoniae [1]